Search

Your search keyword '"Palvarini, L"' showing total 102 results

Search Constraints

Start Over You searched for: Author "Palvarini, L" Remove constraint Author: "Palvarini, L"
102 results on '"Palvarini, L"'

Search Results

2. Weight Gain: A Possible Side Effect of All Antiretrovirals

3. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

4. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

5. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

7. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

8. Weight gain: A possible side effect of all antiretrovirals

13. Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

14. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis

15. No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

16. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

17. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

19. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

20. A novel methodology for large-scale phylogeny partition

21. A novel methodology for large-scale phylogeny partition

22. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

23. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen

24. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

25. Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretroviral Treatment in Clinical Practice

26. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice

27. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

28. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

29. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

30. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

31. Tossicità in HAART contenente Lopinavir/r: Risultati di uno studio di coorte (Progetto Scolta)

32. Risultati preliminari sulla sicurezza di atazanavir/ritonavir (ATZ/RTV) nella terapia antiretrovirale di una coorte di pazienti HIV-1 positivi arruolati nel progetto Scolta

33. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

36. A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

43. Terapia antiretrovirale in pazienti naives ed experienced in condizioni di vita reale: lo studio MASTER-1

44. Renal toxicity in HIV-infected patients receiving HAART includine tenofovir [Tossicità renale in pazienti con infezione da HIV in trattamento con HAART contenente tenofovir]

45. Short-term adverse effects from and discontiuation of antiretroviral post-exposure prophylaxis

46. Long-term efficacy of boosted and unboosted atazanavir-containing regimens: results from the SCOLTA Project

49. Changing patterns of HIV transmission and better targeting for intervention strategies.

50. Renal toxicity in HIV-infected patients receiving HAART includine tenofovir | Tossicità renale in pazienti con infezione da HIV in trattamento con HAART contenente tenofovir

Catalog

Books, media, physical & digital resources